Download PDF

1. Company Snapshot

1.a. Company Description

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States.It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.The company also provides Lapiplasty Mini-Incision precision system.


In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion.Treace Medical Concepts, Inc.was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.

Show Full description

1.b. Last Insights on TMCI

The recent performance of Treace Medical Concepts, Inc. has been negatively impacted by a series of investigations and lawsuits related to potential securities law violations. The company's first quarter 2024 financial results, released after the market closed on May 7, 2024, led to a revision of its full year 2024 guidance, lowering it by approximately $20 million. This development has raised concerns among investors, with several law firms commencing investigations and class action lawsuits against the company.

1.c. Company Highlights

2. Transformational Phase with Bunion Solutions Expansion

The company's fourth quarter revenue was $62.5 million, a 9% decrease compared to the prior year, while gross margin stood at 80.6%, relatively stable compared to 80.7% in the same period last year. The EPS loss was $0.1471, slightly better than the estimated loss of $0.15. Total operating expenses were $56.3 million, up from $55.7 million in the fourth quarter of 2024.

Publication Date: Mar -07

📋 Highlights
  • Revenue Guidance 2026:: $200M–$212M, a 6%–0% decline YoY compared to 2025's $212M+.
  • Cash Burn Reduction:: 50% decrease in 2026 versus 2025, targeting $4M–$6M adjusted EBITDA loss.
  • New Product Adoption:: 25% of 3,300 surgeons have adopted new MIS osteotomy/bunion technologies (e.g., Nanoplasty, Percuplasty).
  • Product Expansion:: Launched biologics (CortIFuse) and new systems (SuperBite, Speed XM), aiming to boost wallet share and ASPs.
  • Long-Term Growth Target:: Mid-single-digit revenue growth aligned with foot/ankle market trends ($62.5M Q4 2025 revenue, -9% YoY).

Guidance and Strategic Focus

For full year 2026, the company initiated revenue guidance in the range of $200 million to $212 million, representing a decline of 6% to 0% compared to full year 2025, with expectations of revenue declines continuing until the seasonally strongest fourth quarter. The company is focused on accelerating bunion procedure volume growth, broadening technology offerings, and increasing wallet share. As Mark Hair mentioned, "We're excited about expanding our product offerings, including the biologics portfolio. We expect good margins on these new products and don't think it will negatively impact our operating margins."

New Product Launches and Market Expansion

The company has launched new bunion technologies, including Nanoplasty and Percuplasty 3D MIS systems, expanding its reach into the high-volume osteotomy segment. The Lapiplasty Lightning platform, launching later in the year, combines next-generation 3D correction instrumentation and SpeedPlate TMT implants. These new products are expected to drive market share gains and improve profitability.

Valuation and Growth Prospects

Analysts estimate next year's revenue growth at 7.7%. The current valuation metrics show a P/S Ratio of 0.43 and an EV/EBITDA of -2.22. With a ROE of -62.19% and ROIC of -33.86%, the company is still in a loss-making phase but is expected to reduce its cash burn by approximately 50% in 2026. The company's strategic focus on expanding its product offerings and increasing wallet share is expected to drive growth and improve profitability.

Future Outlook

The company's confidence in the future is grounded in its past success, and it believes it is well-positioned to accelerate procedure volume growth rates while growing customer wallet share and expanding its total addressable market. The rollout of new products is expected to appeal to new surgeons and drive deeper into the existing customer base, with the goal of increasing bunion procedures.

3. NewsRoom

Card image cap

Treace Medical Concepts Q4 Earnings Call Highlights

Mar -02

Source: defenseworld.net

Card image cap

Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript

Feb -27

Source: seekingalpha.com

Card image cap

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb -27

Source: globenewswire.com

Card image cap

Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference

Feb -24

Source: globenewswire.com

Card image cap

First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

Feb -19

Source: seekingalpha.com

Card image cap

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

Feb -12

Source: globenewswire.com

Card image cap

301,100 Shares in Treace Medical Concepts, Inc. $TMCI Acquired by Acuitas Investments LLC

Jan -30

Source: defenseworld.net

Card image cap

Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan -14

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.00%)

6. Segments

Medical Devices

Expected Growth: 13%

Treace Medical Concepts, Inc.'s 13% growth in Medical Devices is driven by increasing demand for minimally invasive surgical procedures, an aging population, and a growing need for orthopedic and spine treatments. Additionally, advancements in technology, such as robotic-assisted surgery, and strategic partnerships are contributing to the company's growth.

7. Detailed Products

Lapiplasty 3D Bunion Correction

A minimally invasive surgical system for the correction of bunions, utilizing 3D printed titanium implants and a proprietary instrumentation system.

Adductoplasty

A surgical procedure for the correction of hallux valgus interphalangeus, utilizing a proprietary implant and instrumentation system.

Treace Medical Instruments

A range of surgical instruments designed for foot and ankle procedures, including osteotomies, fusions, and soft tissue repairs.

8. Treace Medical Concepts, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Treace Medical Concepts, Inc. has a moderate threat of substitutes due to the presence of alternative medical devices and treatments.

Bargaining Power Of Customers

Treace Medical Concepts, Inc. has a low bargaining power of customers due to the specialized nature of its products and limited customer base.

Bargaining Power Of Suppliers

Treace Medical Concepts, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for its raw materials and components.

Threat Of New Entrants

Treace Medical Concepts, Inc. has a high threat of new entrants due to the growing demand for medical devices and the relatively low barriers to entry in the industry.

Intensity Of Rivalry

Treace Medical Concepts, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 28.29%
Debt Cost 5.79%
Equity Weight 71.71%
Equity Cost 5.79%
WACC 5.79%
Leverage 39.45%

11. Quality Control: Treace Medical Concepts, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
AdaptHealth

A-Score: 4.7/10

Value: 8.4

Growth: 6.4

Quality: 5.2

Yield: 0.0

Momentum: 5.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Hyperfine

A-Score: 4.3/10

Value: 6.9

Growth: 7.4

Quality: 3.3

Yield: 0.0

Momentum: 7.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Apyx Medical

A-Score: 4.0/10

Value: 6.6

Growth: 2.9

Quality: 3.9

Yield: 0.0

Momentum: 10.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Cytosorbents

A-Score: 3.3/10

Value: 7.8

Growth: 4.7

Quality: 3.9

Yield: 0.0

Momentum: 2.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Treace Medical Concepts

A-Score: 3.2/10

Value: 8.7

Growth: 3.3

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Cutera

A-Score: 2.8/10

Value: 10.0

Growth: 1.6

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.35$

Current Price

1.35$

Potential

-0.00%

Expected Cash-Flows